- Home
- CDTX vs DRUG Comparison
CDTX vs DRUG Comparison
Compare CDTX & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDTX | DRUG |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 364.8M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | CDTX | DRUG |
|---|---|---|
| Price | $220.83 | $82.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $128.75 | $83.00 |
| AVG Volume (30 Days) | ★ 947.6K | 164.5K |
| Earning Date | 11-06-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.22 | $23.18 |
| 52 Week High | $221.20 | $97.75 |
Technical Indicators
Market Signals| Indicator | CDTX | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 85.79 | 56.87 |
| Support Level | $219.91 | $77.80 |
| Resistance Level | $221.00 | $89.71 |
| Average True Range (ATR) | 0.54 | 8.40 |
| MACD | -3.90 | -0.81 |
| Stochastic Oscillator | 87.86 | 32.52 |
Price Performance
Historical ComparisonAbout CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.